Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2014, Article ID 931756, 12 pages
http://dx.doi.org/10.1155/2014/931756
Research Article

Clicked Cinnamic/Caffeic Esters and Amides as Radical Scavengers and 5-Lipoxygenase Inhibitors

1Département de Chimie et Biochimie, Université de Moncton, Moncton, NB, Canada E1A 3E9
2Centre de Recherche en Rhumatologie et Immunologie et Faculté de Médecine, Université Laval, Québec, QC, Canada G1V 4G2

Received 13 September 2013; Revised 12 December 2013; Accepted 13 December 2013; Published 18 February 2014

Academic Editor: Patrick Bednarski

Copyright © 2014 Jérémie A. Doiron et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Samuelsson, “Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation,” Science, vol. 220, no. 4597, pp. 568–575, 1983. View at Google Scholar · View at Scopus
  2. M. Peters-Golden and W. R. Henderson Jr., “Mechanisms of disease: leukotrienes,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1798–1854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Israel, P. Rubin, J. P. Kemp et al., “The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma,” Annals of Internal Medicine, vol. 119, no. 11, pp. 1059–1066, 1993. View at Google Scholar · View at Scopus
  4. B. Knorr, J. Matz, J. A. Bernstein et al., “Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial,” The Journal of the American Medical Association, vol. 279, no. 15, pp. 1181–1186, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Suissa, R. Dennis, P. Ernst, O. Sheehy, and S. Wood-Dauphinee, “Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial,” Annals of Internal Medicine, vol. 126, no. 3, pp. 177–183, 1997. View at Google Scholar · View at Scopus
  6. G. Philip, K. Malmstrom, F. C. Hampel Jr. et al., “Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring,” Clinical and Experimental Allergy, vol. 32, no. 7, pp. 1020–1028, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Nayak and R. B. Langdon, “Montelukast in the treatment of allergic rhinitis: an evidence-based review,” Drugs, vol. 67, no. 6, pp. 887–901, 2007. View at Google Scholar · View at Scopus
  8. M. Peters-Golden and W. R. Henderson Jr., “The role of leukotrienes in allergic rhinitis,” Annals of Allergy, Asthma and Immunology, vol. 94, no. 6, pp. 609–669, 2005. View at Google Scholar · View at Scopus
  9. R. Spanbroek, R. Gräbner, K. Lötzer et al., “Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1238–1243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Qiu, A. Gabrielsen, H. E. Agardh et al., “Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 21, pp. 8161–8166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. I. M. Avis, M. Jett, T. Boyle et al., “Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling,” Journal of Clinical Investigation, vol. 97, no. 3, pp. 806–813, 1996. View at Google Scholar · View at Scopus
  12. M. Romano, A. Catalano, M. Nutini et al., “5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor,” The FASEB Journal, vol. 15, no. 13, pp. 2326–2336, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Rioux and A. Castonguay, “Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents,” Carcinogenesis, vol. 19, no. 8, pp. 1393–1400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Chen, N. Li, S. Wang et al., “Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin,” Journal of the National Cancer Institute, vol. 95, no. 14, pp. 1053–1061, 2003. View at Google Scholar · View at Scopus
  15. Z. Sun, S. Sood, N. Li et al., “Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors,” Carcinogenesis, vol. 27, no. 9, pp. 1902–1908, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Ghosh and C. E. Myers, “Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 13182–13187, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Pergola and O. Werz, “5-Lipoxygenase inhibitors: a review of recent developments and patents,” Expert Opinion on Therapeutic Patents, vol. 20, no. 3, pp. 355–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Berger, M. T. M. De Chandt, and C. B. Cairns, “Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease,” International Journal of Clinical Practice, vol. 61, no. 4, pp. 663–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Liu, L. M. Dube, J. Lancaster, L. J. Swanson, L. Rosenstein, and M. McConnell, “Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6- month randomized multicenter trial,” Journal of Allergy and Clinical Immunology, vol. 98, no. 5, pp. 859–871, 1996. View at Google Scholar · View at Scopus
  20. L. García-Marcos, A. Schuster, and E. G. Pérez-Yarza, “Benefit-risk assessment of antileukotrienes in the management of asthma,” Drug Safety, vol. 26, no. 7, pp. 483–518, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Touaibia, J. Jean-François, and J. Doiron, “Caffeic acid, a versatile pharmacophore: an overview,” Mini-Reviews in Medicinal Chemistry, vol. 11, no. 8, pp. 695–713, 2011. View at Google Scholar · View at Scopus
  22. H. Cho, M. Ueda, M. Tamaoka et al., “Novel caffeic acid derivatives: extremely potent inhibitors of 12-lipoxygenase,” Journal of Medicinal Chemistry, vol. 34, no. 4, pp. 1503–1505, 1991. View at Google Scholar · View at Scopus
  23. G. F. Sud'ina, O. K. Mirzoeva, M. A. Pushkareva, G. A. Korshunova, N. V. Sumbatyan, and S. D. Varfolomeev, “Caffeic acid phenethyl ester as a lipoxygenase inhibitor with antioxidant properties,” FEBS Letters, vol. 329, no. 1-2, pp. 21–24, 1993. View at Publisher · View at Google Scholar · View at Scopus
  24. O. K. Mirzoeva and P. C. Calder, “The effect of propolis and its components on eicosanoid production during the inflammatory response,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 6, pp. 441–449, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-F. Lin, T.-C. Chang, C.-C. Chiang, H.-J. Tsai, and L.-Y. Hsu, “Synthesis of selenium-containing polyphenolic acid esters and evaluation of their effects on antioxidation and 5-lipoxygenase inhibition,” Chemical and Pharmaceutical Bulletin, vol. 53, no. 11, pp. 1402–1407, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. L. H. Boudreau, J. Maillet, L. M. LeBlanc et al., “Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes,” PLoS ONE, vol. 7, no. 2, Article ID e31833, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Doiron, L. H. Boudreau, N. Picot, B. Villebonet, M. E. Surette, and M. Touaibia, “Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoylclusters,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 4, pp. 1118–1121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. L. H. Boudreau, N. Picot, J. Doiron et al., “Caffeoyl and cinnamoyl clusters with anti-inflammatory and anti-cancer effects. Synthesis and structure-activity relationship,” New Journal of Chemistry, vol. 33, no. 9, pp. 1932–1940, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. G. W. Carter, P. R. Young, D. H. Albert et al., “5-Lipoxygenase inhibitory activity of zileuton,” Journal of Pharmacology and Experimental Therapeutics, vol. 256, no. 3, pp. 929–937, 1991. View at Google Scholar · View at Scopus
  30. S. Whitman, M. Gezginci, B. N. Timmermann, and T. R. Holman, “Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase,” Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 2659–2661, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Pontiki and D. Hadjipavlou-Litina, “Lipoxygenase inhibitors: a comparative QSAR study review and evaluation of new QSARs,” Medicinal Research Reviews, vol. 28, no. 1, pp. 39–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Pergola, B. Jazzar, A. Rossi et al., “Cinnamyl-3,4-dihydroxy-α-cyanocinnamate is a potent inhibitor of 5-lipoxygenase,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 1, pp. 205–213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. W. S. Horne, M. K. Yadav, C. D. Stout, and M. R. Ghadiri, “Heterocyclic peptide backbone modifications in an α-helical coiled coil,” Journal of the American Chemical Society, vol. 126, no. 47, pp. 15366–15367, 2004. View at Google Scholar · View at Scopus
  34. V. D. Bock, D. Speijer, H. Hiemstra, and J. H. Van Maarseveen, “1,2,3-Triazoles as peptide bond isosteres: synthesis and biological evaluation of cyclotetrapeptide mimics,” Organic and Biomolecular Chemistry, vol. 5, no. 6, pp. 971–975, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. H. C. Kolb and K. B. Sharpless, “The growing impact of click chemistry on drug discovery,” Drug Discovery Today, vol. 8, no. 24, pp. 1128–1137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J.-F. Lutz and Z. Zarafshani, “Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne “click” chemistry,” Advanced Drug Delivery Reviews, vol. 60, no. 9, pp. 958–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Mayer and M. E. Maier, “Design and synthesis of a tag-free chemical probe for photoaffinity labeling,” European Journal of Organic Chemistry, no. 28, pp. 4711–4720, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. L.-Y. Wu, Y.-X. Xie, Z.-S. Chen, Y.-N. Niu, and Y.-M. Liang, “A convenient synthesis of 1-substituted 1,2,3-triazoles via CuI/Et3N catalyzed 'click chemistry' from azides and acetylene gas,” Synlett, no. 9, pp. 1453–1456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. N. Kunesch, C. Meit, and J. Poisson, “Utilisation de la guanidine comme agent désacétylant sélectif: une method de désacétylation instantanée applicable aux sucres,” Tetrahedron Letters, vol. 28, pp. 3569–3572, 1987. View at Google Scholar
  40. S. Son and B. A. Lewis, “Free radical scavenging and antioxidative activity of caffeic acid amide and ester analogues: structure-activity relationship,” Journal of Agricultural and Food Chemistry, vol. 50, no. 3, pp. 468–472, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Gaspar, E. M. Garrido, M. Esteves et al., “New insights into the antioxidant activity of hydroxycinnamic acids: synthesis and physicochemical characterization of novel halogenated derivatives,” European Journal of Medicinal Chemistry, vol. 44, no. 5, pp. 2092–2099, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Sugiyama and A. Hirota, “New potent DPPH radical scavengers from a marine-derived actinomycete strain USF-TC31,” Bioscience, Biotechnology and Biochemistry, vol. 73, no. 12, pp. 2731–2734, 2009. View at Publisher · View at Google Scholar · View at Scopus